With President Donald Trump’s recent announcement of 50% tariffs on copper imports under Section 232 of the Trade Expansion Act, the United States has correctly identified copper as a material of strategic national importance.
The Senate’s decision to remove the FEOC Excise Tax and weaken FEOC restrictions is a blatant giveaway to the Chinese Communist Party’s solar industry.
CPA strongly endorses the FEOC Excise Tax in the Senate reconciliation bill as a critical step in protecting America’s solar manufacturing industry from reliance on subsidized and compromised Chinese components.
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicine. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe.
The Department’s decision confirms what CPA has consistently warned: Chinese solar companies have been illegally circumventing U.S. trade laws through Southeast Asian shell operations, flooding the U.S. market with dumped and subsidized products directly harming the domestic solar manufacturing industry.
The United States is amid a dangerous drug shortage that endangers patients, undermines our health care system and exposes a deep vulnerability to national security. America’s overwhelming reliance on foreign manufacturers for generic drugs is at the center of it.
Break out the Grizzly cooler and fire up the Broilmaster—it’s Liberation Day. In President Trump’s words, April 2 marks the end of the US of A being “ripped off by virtually every country in the world.”
The National Institutes of Health (NIH) is today the main source of new drugs in this country – indeed the world, because America leads in the field. It has a critical importance to America’s health. Less well known is its huge, positive, economic impact.
